The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2011Development of Posiphen to Treat Parkinson's Disease
Objective/Rationale:
Posiphen is a small molecule drug that inhibits expression of alpha-synuclein, a protein involved in Parkinson's disease (PD) pathogenesis. We propose studies in a pre-clinical... -
Target Validation, 2011Validation of Skp1 as a New Target for PD Therapy
Objective/Rationale:
Multiple evidence supports the notion that a malfunction of the ubiquitin-proteasome system and autophagy plays a crucial role in protein misfolding and aggregation in Parkinson... -
LRRK2, 2011DAT Imaging in Unaffected LRRK2 Gene Positive Subjects in a Chinese Community Cohort
Objective/Rationale:
While most PD is not associated with a specific genetic cause, the genetic mutation affecting the LRRK2 gene has been identified as a cause of PD in selected families and... -
MJFF Research Grant, 2011Laboratory Phenotyping of Parkinson Disease Subjects Using a Multiplex Approach
Promising Outcomes of Original Grant:
With the original funded grant we have successfully optimized the measurement of total alpha-synuclein and DJ-1 in cerebrospinal fluid as promising markers for... -
MJFF Research Grant, 2011Caspase- 1 Inhibition to Reduce Cleaved Alpha-synuclein in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
We will test the hypothesis that caspase-1 inhibition will down- regulate α-synuclein (α-SYN) at mRNA and/or protein levels within the SN and restore impaired function of the... -
Defining Cognitive Phenotypes of Parkinson’s Disease, 2011Development of Multimodal Imaging Biomarkers for Cognitive Dysfunction in Parkinson's Disease
Objective/Rationale:
By the time a person with Parkinson’s disease (PD) meets diagnostic criteria for dementia, the brain has already been ravaged. Unfortunately, current clinical, neuropsychological...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.